Apolipoprotein E promotes papillary thyroid carcinoma progression by activating PINK1/Parkin-mediated mitophagy Authors: Sinuo Sun, Suwei Zuo, Yanmeng Zhou, Jiayin Song, Yuanyuan Wang, Shibo Liu, Gang Xue, Xu Lin, Jingfang Wu Published: 2026 ABSTRACT BackgroundIncreasing evidence supports a progression-related role of apolipoprotein E (APOE) in papillary thyroid carcinoma (PTC), yet a clear mechanistic explanation for this association is still lacking. Considering the pivotal role of mitochondrial homeostasis in tumorigenesis, the potential role of APOE in promoting PTC progression through mitophagy regulation was investigated. Additionally, the involvement of the PINK1/Parkin-associated pathway in this process was examined to provide insights into its contribution to tumor progression.MethodsAPOE in thyroid carcinoma was characterized in terms of its expression profile, diagnostic relevance, and potential biological functions, based on integrative evidence derived from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. APOE and mitophagy-related protein expression were further examined in PTC tissues by immunohistochemistry. Further evaluation of APOE in PTC cell lines focused on its association with proliferation, apoptosis, and mitophagy, with bidirectional functional perturbation serving as the basis for assessment. Pharmacological inhibitors were used to assess the involvement of mitophagy-related signaling in the observed APOE-dependent phenotypes. Additionally, the in vivo impact of APOE on PTC tumor growth and mitophagy was further investigated through a nude mouse xenograft model, providing insight into its potential role in tumor progression.ResultsA significant upregulation of APOE was observed in thyroid carcinoma tissues and PTC cell lines, supporting its potential relevance as a diagnostic biomarker. The modulation of APOE expression significantly influenced PTC cell proliferation and apoptosis, with overexpression promoting cell proliferation and inhibiting apoptosis, while knockdown led to the opposite effects. Mechanistically, APOE overexpression increased AMP-activated protein kinase (AMPK) phosphorylation and decreased mammalian target of rapamycin (mTOR) phosphorylation, accompanied by increased PINK1 and Parkin expression and mitophagy-related changes, including altered mitochondrial membrane potential, reduced overall reactive oxygen species levels, and increased autophagosome formation. Pharmacological inhibition of mitophagy attenuated the proliferative and antiapoptotic effects of APOE.ConclusionsThese findings demonstrate that APOE promotes PTC progression in association with PINK1/Parkin-related mitophagy and modulation of the AMPK/mTOR axis. The APOE-associated mitophagy axis may provide a rationale for future preclinical investigation in PTC. Highlight box Key findings • Apolipoprotein E (APOE) was highly expressed in papillary thyroid carcinoma (PTC) tissues and cells. • APOE promoted PTC cell proliferation, inhibited apoptosis, and was associated with activation of PINK1/Parkin-related mitophagy via the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway. What is known and what is new? • Mitophagy is involved in tumor progression and metabolic adaptation in multiple cancers. APOE has been reported to participate in tumor development; however, its specific role in PTC remains unclear. • This study suggests that APOE is upregulated in PTC tissues and cell lines and is associated with enhanced proliferation and reduced apoptosis in PTC cells. APOE may contribute to PTC progression in association with PINK1/Parkin-related mitophagy and modulation of the AMPK/mTOR signaling axis. What is the implication, and what should change now? • This study provides new mechanistic insight into the role of APOE in PTC progression. • Further in vivo and preclinical studies are needed to validate the biomarker and therapeutic relevance of APOE-associated signaling in PTC. Introduction Thyroid carcinoma (THCA) ranks among the most rapidly rising malignancies of the endocrine system worldwide (1). Accounting for nearly 80% of thyroid malignancies, papillary thyroid carcinoma (PTC) constitutes the predominant histological subtype (2). Although the majority of individuals with THCA achieve favorable outcomes after conventional therapies such as thyroidectomy and radioactive iodine ablation (3), a subset of PTC patients exhibit more aggressive characteristics, including lymph node metastasis, local recurrence, and de-differentiation, leading to drug resistance and increased mortality (4). Notably, THCA comprises multiple histological subtypes with distinct molecular features and biological behaviors. To minimize biological heterogeneity and enable a more rigorous mechanistic investigation, this study focused on PTC as a representative and clinically predominant subtype of THCA. A detailed understanding of the molecular mechanisms governing the development, progression, and metastasis of PTC is imperative for improving outcomes in patients with PTC as well as identifying novel therapeutic targets. The influence of apolipoprotein E (APOE) on lipid metabolism is profound, and it has emerged as a central focus of research in both Alzheimer’s disease and cardiovascular disorders (5). In recent years, accumulating evidence indicates that APOE exhibits abnormally elevated expression in multiple malignant tumors, including pancreatic carcinoma (6), bladder cancer (7), ovarian cancer (8), and glioblastoma (9). Current evidence suggests that APOE facilitates PTC progression by modulating macrophage polarization, which is associated with elevated tumor cell proliferation and reduced apoptotic sensitivity (10). However, whether APOE influences the malignant progression of PTC through mitophagy remains unclear. As the central organelle responsible for cellular energy metabolism and the regulation of apoptosis, cellular homeostasis is fundamentally dependent on the quality control and functional integrity of the mitochondria (11). Mitophagy, a selective form of autophagy, eliminates dysfunctional or excess mitochondria, a process essential to preserve mitochondrial integrity while also supporting cellular equilibrium (12). Mitophagy plays a dual role in the context of cancer: it inhibits tumorigenesis by removing dysfunctional mitochondria, yet, under stress conditions, mitophagy sustains cellular energy metabolism and preserves reactive oxygen species (ROS) balance, thereby promoting the survival and proliferation of tumor cells (13). Mitophagy is achieved via a variety of interconnected, yet mechanistically distinct, pathways. They can be categorized as ubiquitin-dependent or non-ubiquitin-dependent. The PINK1/Parkin signaling axis has been extensively characterized as a ubiquitin-dependent regulatory cascade; however, its precise role in PTC remains unclear. In addition, LC3-interacting region (LIR) motif-containing proteins localized at the mitochondrial outer membrane can directly interact with LC3, mediating ubiquitin-independent mitophagy pathways (14). However, the role of mitophagy in PTC progression, its upstream regulators, and underlying mechanisms remain unclear. Previous studies suggest that APOE regulates cellular autophagy and mitochondrial function. Lu et al. reported that APOE regulates mitochondrial function and oxidative balance in hepatocytes via the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR)-autophagy axis while its deficiency impairs p-AMPK and Beclin1 expression, causing metabolic disorders and liver injury (15). Schmukler et al. reported altered mitochondrial dynamics in APOE4 expression astrocytes, suggesting that APOE isoforms may influence the structural and functional stability of mitochondria (16). Additionally, Díaz-Gago et al. showed that autophagy activation promotes resistance to BRAFV600E inhibitors in thyroid cancer (17). Together, these findings indicate that APOE may influence tumor progression through autophagy, especially mitophagy, although the molecular mechanisms remain unclear. Although APOE is reported to be dysregulated in PTC (10), limited insight into its precise biological role and its mechanistic contribution to PTC progression remains a major barrier to a deeper understanding of this disease. The role of APOE in regulating mitophagy, a vital process for mitochondrial quality control and tumor cell survival, in the context of PTC development remains unclear and warrants further exploration. Therefore, the present study aimed to systematically investigate the expression pattern and functional role of APOE in PTC, with a specific focus on its association with mitophagy-related changes and the AMPK/mTOR and PINK1/Parkin signaling axes. By integrating the analyses of clinical specimens with in vitro functional assays, rescue experiments, and in vivo xenograft models, we sought to clarify the role of the APOE-mitophagy axis in the regulation of PTC cell proliferation, apoptosis, and clonogenic capacity. These findings were intended to provide mechanistic insight into PTC progression and to inform future preclinical studies. We present this article in accordance with the MDAR and ARRIVE reporting checklists (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0796/rc). Methods Bioinformatic methods Acquisition of THCA transcriptomic and corresponding clinical data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases provided a comprehensive dataset for subsequent analyses. By examining APOE expression across THCA and normal adjacent tissues, this study identified its diagnostic significance, confirmed via receiver operating characteristic (ROC) curve evaluation. We used TCGA database data to examine the co-expression of APOE with genes involved in mitophagy. Using TCGA data, samples were categorized according to median APOE expression levels. Genes exhibiting significant differential expression [|log2fold change (FC)| >1, false discovery rate (FDR) <0.05] were identified and further analyzed through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment methods, providing insights into their biological roles. By employing CIBERSORT and Tumor Immune Estimation Resource (TIMER), this study examined the connection between APOE expression and immune cell infiltration, specifically macrophages. Immunohistochemistry (IHC) Collection of paired tumor and adjacent normal tissues from 68 PTC patients provided a foundation for comparative analyses. A total of 58 samples were supplied in tissue microarray format (ThyP120CS02) by Shanghai Superbiotek Co., Ltd., an additional 10 paired tissue samples were obtained from patients with PTC who underwent surgery at the Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Hebei North University, between March 2023 and March 2024. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. The study was approved by the Ethics Committee of The First Affiliated Hospital of Hebei North University (approval No. K2024029). All participants provided written informed consent. The inclusion criteria were established as follows: (I) patients who initially presented to the Head and Neck Surgery and Otorhinolaryngology Department at a tertiary teaching hospital; (II) histologically confirmed PTC; (III) planned surgical intervention, encompassing total or partial thyroidectomy with lymphadenectomy; (IV) and availability of all preoperative test results, electronic records, and postoperative pathological findings. A total of 68 patients were enrolled, including 23 males and 45 females. The tumor tissue sections from the tumor-bearing mice analyzed in this study were derived from a previously published animal experiment (10). Experimental animals were purchased from SBF (Beijing) Biotechnology Co., Ltd. and maintained under SPF conditions, thereby supporting environmental stability for subsequent observation (12-h light/dark cycle, 22±2 ℃, 50%±10% humidity). All animal experiments were performed under a project license (No. K2023023) granted by the Experimental Animal Ethics Committee of SBF (Beijing) Biotechnology Co., Ltd., in compliance with national guidelines for the care and use of animals of China. After fixation with formalin, the tissues were paraffin-embedded and processed into sections of 4 µm thickness. Protein expression levels were evaluated via IHC staining for APOE (1:100; ZENBIO, #381129), P62 (1:150; Affinity, #AF5384), TOMM20 (1:150; Affinity, #AF5206), TIM23 (1:250; Proteintech, #11123-1-AP), and Beclin1 (1:150; Affinity, #AF5128) in tissue samples. Deparaffinization, rehydration, and antigen retrieval were carried out to prepare the tissue sections for subsequent analysis. Antigen-antibody interactions were promoted through overnight incubation of the sections with the primary antibodies at 4 ℃. On day 2, the sections were incubated with horseradish peroxidase (HRP)-labeled secondary antibodies (Servicebio, China). Chromogenic detection was conducted using 3,3’-diaminobenzidine (DAB), and nuclei were lightly counterstained with hematoxylin. The samples were dehydrated, cleared, mounted, and subjected to microscopic observation and image capture. Cell culture and transfection The PTC-derived cell lines (BCPAP, K1, and TPC-1), along with the normal thyroid epithelial cell line Nthy-ori3–1, were sourced from Benna Union Biotechnology Co., Ltd. (China). These cells were cultured in RPMI-1640 medium (Bio-Channel, #BC-M-017, China), supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin (Solarbio, #P1400, China), ensuring optimal conditions for cell growth. To maintain cellular viability and promote consistent growth, cells were incubated under standard conditions (37 ℃, 5% CO2). This environment facilitated subsequent experimental processes by providing a stable culture foundation. The transfection of TPC-1 cells was carried out using either a control plasmid or an APOE overexpression (OE) plasmid, both from Heshen Co., Ltd., China (#w-5951), using Lipofectamine™2000 (Invitrogen, #11668-019, USA) to establish the APOE intervention model. K1 cells were transfected with three different APOE-targeting shRNAs (designated shRNA#1-3) as well as a negative control plasmid (shRNAC) purchased from Heshen Co., Ltd., China (#w-5998). Two distinct experimental groups were established for subsequent functional assays: the OE group, which included APOE-overexpressing TPC-1 cells along with their respective negative controls, and the knockdown group, which comprised K1 cells harboring the control vector or one of the three APOE shRNAs. In drug treatment experiments, OE-APOE group cells were further grouped into: control group treated with dimethyl sulfoxide (DMSO), MG149 treatment group (20 µM, MCE, #HY-15887, USA), and 3-methyladenine (3MA) treatment group (20 µM, Solarbio, #IM0190, China). Cells were collected for analysis after 24 h of treatment. Western blot Following total cellular protein extraction with radioimmunoprecipitation assay (RIPA) buffer (Applygen, #P1250, China), protein concentration was determined by the bicinchoninic acid (BCA) method, thereby ensuring normalized loading and improving the reliability of subsequent analysis. To ensure equal protein loading, samples were adjusted to comparable concentrations, followed by resolution through sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and subsequent transfer onto polyvinylidene fluoride (PVDF) membranes (Beyotime, #FFP39, China), facilitating downstream analysis. To prevent nonspecific interactions, the membranes were pretreated for 1 h with blocking buffer containing 5% nonfat dry milk at ambient temperature, and primary antibody incubation was subsequently carried out at 4 ℃ overnight. Antibodies were used to detect different categories of target proteins. In the present study, APOE was identified as the principal protein of interest. The expression of p62, TOMM20, TIM23, Beclin1, and LC3II/I was analyzed to characterize mitophagy, whereas that of PINK1, Parkin, AMPK, p-AMPK, mTOR, and p-mTOR was examined to elucidate the associated signaling pathways. Bcl-2, BAX, Caspase-3 and Cleaved-Caspase-3 were assessed, serving as molecular indicators of apoptosis. Washing with Tris-buffered saline containing Tween-20 (TBST) was performed following primary antibody incubation, ensuring the removal of non-specifically bound immunoglobulins and improving signal specificity. Table S1 provides detailed information regarding antibody suppliers, catalog numbers, and dilutions. HRP-conjugated secondary antibodies were used for 1-hour incubation at ambient temperature, enabling protein visualization through a Chemiluminescence Gel Imaging System (Aplegen, USA). Quantitative real-time polymerase chain reaction (RT-qPCR) RNA extraction using the TRIzol method (LabLead, #R1000, China) and subsequent cDNA synthesis with a reverse transcription kit (#KR116-02; Taingen, Germany) enabled the quantification of gene expression. Quantitative PCR, performed via the SYBR Green method (Biosharp, #BL698A, China) on a Quantstudio3 system, allowed assessment of relative mRNA levels using the 2−ΔΔCt algorithm, with β-actin serving as a housekeeping gene for normalization. Primer sequences are provided in Table S2. Immunocytochemistry (ICC) Cellular structural preservation and membrane permeabilization were ensured by PBS washing, fixation with 4% paraformaldehyde, and exposure to 0.8% Triton X-100. After blocking and hydrogen peroxide treatment, sections were maintained at 4 ℃ overnight with the APOE antibody (1:250, ZENBIO, #381129, China). The following day, a secondary antibody conjugated to HRP was used, followed by DAB chromogenic development and hematoxylin counterstaining. Samples were dehydrated using an alcohol gradient, cleared in xylene, and observed for protein localization and expression using an optical microscope. Immunofluorescence (IF) Sterile glass coverslips were used to plate the cells in six-well culture dishes. After cell adhesion, the samples were fixed in 4% paraformaldehyde for 30 min to preserve their morphology, followed by permeabilization with 0.8% Triton X-100 for 5 min to facilitate antibody access. Subsequently, blocking with 5% BSA for 1 h, the samples were incubated using primary antibodies—Beclin1 (1:180, Affinity, #AF5128, China), TOMM20 (1:150, Affinity, #AF5206, China), TIM23 (1:250, Proteintech, #11123-1-AP, China), and P62 (1:150, Affinity, #AF5384, China)—at 4 ℃ for approximately 16 h. Following PBS rinsing, fluorophore-labeled secondary antibodies were added and incubated for 1h under ambient conditions in the dark to minimize photobleaching, followed by 5 min of nuclear staining with 4’,6-diamidino-2-phenylindole (DAPI) (Beyotime; #P0131, China). Samples were mounted and visualized using fluorescence microscopy to assess signal intensity. MitoSOX detection MitoSOX Red (#M4830; Solarbio, China) was used to measure mitochondrial ROS levels. During rapid cell growth, cells were collected and underwent two washes in serum-free RPMI 1640 medium to remove residual culture medium, followed by incubation with 6 µM MitoSOX Red under serum-free conditions during a 25 min incubation at 37 ℃ in darkness to evaluate mitochondrial superoxide levels. Post-incubation, three PBS washes were performed on the cells to eliminate residual culture medium, enabling further analysis. Once prepared, observations were made and fluorescence signals were captured and recorded using a microscope system tailored for 510 nm excitation and 580 nm emission. Detection of total ROS levels Cellular ROS levels were evaluated by staining the cells with the oxidant-sensitive dye 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) (LabLead, #0041-100t, China). Following PBS washes, cells were subjected to DCFH-DA treatment (8 µM in serum-free medium) at 37 ℃ for 25 min in darkness. Post-incubation, cells underwent three rounds of PBS washing, followed by observation and photography under a fluorescence microscope. These results reflect changes in the overall intracellular ROS levels. Assessment of mitochondrial membrane potential by JC-1 staining Assessment of mitochondrial membrane potential was performed in adherent cultures grown in six-well plates. Following PBS washes, JC-1 staining (5 µg/mL, Solarbio, #IJ0300, China) was performed at 37 ℃ for 25 min in darkness to label mitochondria according to membrane potential, with subsequent triple PBS rinses. The cells were then imaged under a fluorescence microscope to determine the red/green ratio. Ultrastructural analysis by transmission electron microscopy (TEM) After trypsin digestion and collection, cells were fixed in 2.5% glutaraldehyde for 2 h. Residual fixative was removed through three successive PBS rinses, and the samples were then post-treated with 1% osmium tetroxide for 1 hour. The samples underwent dehydration using an ethanol series graded from 50% to 100%. Following acetone permeabilization, specimens were embedded in epoxy resin for polymerization. Ultrathin sections of approximately 70 nm were prepared and mounted onto copper grids. For structural contrast, sequential staining with uranyl acetate and lead citrate was performed. Mitochondrial morphology and autophagosome structures were then evaluated using TEM. Mitophagy was quantitatively evaluated using TEM. For each sample, the mitophagy ratio per cell was calculated as the number of mitochondria within autophagosomes or autolysosomes divided by the total number of mitochondria per cell. Quantification was performed in randomly selected cells from multiple TEM fields by investigators blinded to the group allocation. Functional assays Cell proliferation was assessed using a Cell Counting Kit-8 (CCK-8) detection kit (HUILAN BIOTECH, KE1090, China), with absorbance measured at 450 nm following a 1-hour incubation with 10 µL of reagent in a 96-well plate, where approximately 1×104 cells were seeded. Colony formation, indicative of cell growth potential, was evaluated by seeding 1×10³ cells into six-well plates and culturing for 10 days. Colonies were fixed with 4% paraformaldehyde, stained with crystal violet, and counted following imaging. Apoptosis was quantified through Annexin V-FITC/PI dual staining, followed by flow cytometry analysis. Statistical methods All experiments were performed with at least three independent biological replicates, and data are presented as the mean ± standard deviation (SD). For each biological replicate, technical replicates were performed as appropriate. Statistical significance was assessed using an independent-samples t-test for comparisons between two groups, while one-way analysis of variance (ANOVA) was used for comparisons among multiple groups. All statistical analyses were performed using GraphPad Prism 9.0 software. A P value <0.05 was considered statistically significant. Results Expression characteristics, functional analysis of APOE in THCA To explore the possible involvement of APOE in THCA development, we initially assessed its expression in THCA tissues (Figure 1). Analysis of the GEO database indicated that APOE was significantly upregulated in tumor tissues compared to adjacent normal tissues (P<0.05, Figure 1A,1B). Analysis of the TCGA database revealed a significant upregulation of APOE in THCA tumor tissues compared with adjacent normal tissues (P<0.05, Figure 1C,1D), indicating its potential involvement in tumor progression. Considering the significantly elevated expression of APOE in THCA tissues, we assessed its feasibility in THCA diagnosis. ROC evaluation demonstrated that APOE had a strong diagnostic capability; the calculated area under the curve was 0.779, and the corresponding 95% confidence range spanned 0.724–0.833 (Figure S1), suggesting its potential as a diagnostic biomarker of THCA. To elucidate APOE function, we performed comparative transcriptomic profiling of APOE by stratifying samples from TCGA dataset into cohorts with elevated and reduced expression levels, identifying 789 upregulated genes and 615 downregulated genes (Figure 1E). GO assessment revealed that the differentially expressed genes (DEGs) were mainly enriched organic anion transport, organic hydroxy compound transport, and diverse transmembrane transporter activities (Figure 1F). Significant enrichment of immune-related signaling pathways was observed in the gene sets with elevated APOE expression, as indicated by gene set enrichment analysis (GSEA) analysis (Figure 1G), whereas the group with low APOE expression primarily exhibited enrichment in metabolism-related pathways (Figure 1H). Building on these findings, the relationship between APOE expression and the immune microenvironment was further explored from an immunological perspective. A positive association was observed between APOE expression and the infiltration of macrophages as well as resting myeloid dendritic cells, whereas an inverse relationship was noted for activated myeloid dendritic cells. Correlation analysis among immune cells showed that macrophages positively correlated with neutrophils (Figure 1I). In summary, APOE was significantly overexpressed in THCA and its diagnostic potential was demonstrated. Furthermore, it may promote tumorigenesis and cancer progression by regulating immune responses and metabolic processes. Expression patterns, functional implications, and immune microenvironment associations of APOE in thyroid carcinoma. (A) GEO database analysis (GSE33630) comparing APOE expression between THCA and adjacent normal tissue. (B) Validation of APOE expression alterations in THCA using GEO paired samples. (C) Comparative analysis of APOE expression in THCA versus adjacent normal tissue using data from the TCGA public dataset. (D) Analysis of APOE transcript abundance in TCGA-matched thyroid cancer specimens. (E) A volcano plot visualizing transcriptional changes across TCGA samples divided into APOE-high and APOE-low subgroups. Genes showing significant up-regulation are marked in red, those with reduced expression levels are highlighted in cyan, while genes without statistically significant changes are shown in neutral tones. (F) GO functional profiling was performed on the screened DEGs. (G) GSEA analysis showed immune-associated signaling routes prominently represented in samples with elevated APOE expression. (H) GSEA analysis showed primary enrichment of metabolism-related pathways in low APOE expression samples. (I) Association of APOE levels with immune microenvironment characteristics. (J) Quantitative analysis of APOE immunohistochemical staining in PTC and adjacent tissues. (K) APOE protein expression was quantitatively analyzed in the thyroid epithelial cell line Nthy-ori3-1 and PTC-derived cell lines (K1, TPC-1, and BCPAP) via Western blot. (L) Relative APOE mRNA levels were quantified in Nthy-ori3-1 and PTC cell lines (K1, TPC-1, BCPAP) using RT-qPCR. (M) IHC analysis was performed to assess APOE protein expression in PTC specimens compared to adjacent non-cancerous tissues (magnification: ×400). (N) Western blot was utilized to detect APOE protein levels in Nthy-ori3-1 and three PTC-derived cell lines (K1, TPC-1, and BCPAP). **, P<0.01; ***, P<0.001; ****, P<0.0001. APOE, apolipoprotein E; DEG, differentially expressed gene; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; IHC, immunohistochemistry; IOD, integrated optical density; KEGG, Kyoto Encyclopedia of Genes and Genomes; PTC, papillary thyroid carcinoma; RT-qPCR, quantitative real-time polymerase chain reaction; TCGA, The Cancer Genome Atlas; THCA, thyroid carcinoma; TPM, transcripts per million. Upregulation of APOE in PTC samples For additional confirmation of APOE expression in PTC, IHC staining was performed on PTC tissue samples (Figure 1). The results revealed a marked upregulation of APOE expression in PTC specimens (P<0.05; Figure 1J,1M). A notable reduction of APOE expression was observed in the Nthy-ori3-1 cell line relative to malignant PTC cell lines, highlighting its potential role in tumor progression (P<0.05, Figure 1K,1L,1N). Significantly elevated APOE expression levels have been observed in PTC, implying its possible involvement in tumor development and its value as a diagnostic indicator. APOE promotes tumor cell proliferation while inhibits apoptotic activity in PTC The impact of APOE on PTC cell growth and apoptosis was investigated, we established an APOE OE model in TPC-1 cells (OE-APOE group) and an APOE-knockdown model in K1 cells (sh-APOE group). The model construction and validation results are shown in Figure 2, and the functional results are shown in Figure 3. OE and knockdown efficiencies were assessed using RT-qPCR, western blot analysis, and ICC. APOE was upregulated under OE conditions (P<0.05, Figure 2A,2D,2F,2H,2I), while a significant decrease of APOE protein levels was detected in cells subjected to shRNA constructs #1 and #3, compared to those carrying the control plasmid (P<0.05, Figure 2B,2C,2E,2G,2J,2K). The CCK-8 assay indicated that APOE upregulation markedly promoted the proliferation of PTC cells (Figure 3M). Conversely, APOE silencing significantly inhibited cell proliferation (Figure 3N). Colony formation assays demonstrated that APOE OE markedly augmented the clonogenic potential of TPC-1 cells (P<0.05; Figure 3A,3C), while a significant decrease in colony formation was observed following APOE knockdown in K1 cells (P<0.05; Figure 3B,3D). Furthermore, flow cytometry revealed a significant reduction in apoptosis following APOE OE (P<0.05, Figure 3E,3G), which was accompanied by decreased levels of Bax, Caspase-3, and Cleaved-Caspase-3, as well as an upregulation of Bcl-2 protein expression (P<0.05, Figure 3I,3K). Conversely, the downregulation of APOE expression markedly increased the rate of apoptosis (P<0.05, Figure 3F,3H,3J,3L). In summary, the promotion of malignant behavior in PTC cells by APOE is driven by its enhancement of cell proliferation and inhibition of apoptosis. Analysis of APOE overexpression and knockdown within PTC cell lines. (A) Western blot analysis was performed to assess APOE expression in TPC-1 cells following overexpression. (B) APOE expression following knockdown in K1 cell line was evaluated using Western blot. (C) APOE levels after knockdown with shRNA#1-3 in K1 cell line were detected by RT-qPCR. (D) Quantification of APOE protein levels in TPC-1 cells following overexpression, assessed by Western blot. (E) Quantitative evaluation of APOE protein expression in K1 cells after knockdown, performed via Western blot. (F) Measurement of APOE transcriptional levels in TPC-1 cells upon overexpression, determined by RT-qPCR. (G) APOE mRNA levels were quantified via RT-qPCR following knockdown in K1 cell line. (H) APOE expression was assessed by ICC after overexpression in TPC-1 cell line. (I) APOE expression in the overexpression group quantified by ICC. (J) APOE expression in the knockdown group quantified by ICC. (K) APOE expression was assessed by ICC after knockdown in K1 cell line. ns, P≥0.05; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. APOE, apolipoprotein E; ICC, immunocytochemistry; IOD, integrated optical density; ns, not significant; OE, overexpression; OENC, overexpression negative control; PTC, papillary thyroid carcinoma; RT-qPCR, quantitative real-time polymerase chain reaction. APOE promotes cell growth and inhibits apoptotic processes in PTC cells. (A) Clonal proliferation in TPC-1 cells following APOE overexpression, assessed by colony formation assay. (B) Colony formation in K1 cells after APOE knockdown, evaluated to examine clonal proliferation. (C) Quantification of colony formation in TPC-1 cells upon APOE overexpression. (D) Quantitative assessment of colony formation in K1 cells after APOE knockdown. (E) Apoptotic levels in TPC-1 cells following APOE overexpression, analyzed by flow cytometry. (F) Flow cytometric evaluation of apoptosis in K1 cells upon APOE knockdown. (G) Quantitative measurement of apoptotic TPC-1 cells after APOE overexpression. (H) Assessment of apoptotic K1 cells following APOE knockdown. (I) Expression of apoptosis-associated proteins in the APOE overexpression group, examined by Western blot. (J) Apoptosis-related protein levels in the APOE knockdown group, determined by Western blot analysis. (K) Quantitative analysis of apoptosis-associated protein expression in the APOE overexpression group by Western blot. (L) Quantitative analysis of apoptosis-associated protein expression in the APOE knockdown group by Western blot. (M) Cell viability in PTC following APOE overexpression was measured with the CCK-8 assay. (N) Cell viability in PTC following APOE knockdown was measured with the CCK-8 assay. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. APOE, apolipoprotein E; CCK-8, Cell Counting Kit-8; OE, overexpression; OENC, overexpression negative control; OD, optical density; PTC, papillary thyroid carcinoma. APOE is associated with mitophagy-related changes in PTC Previous studies have indicated that APOE deficiency leads to impaired mitochondrial function (18). Therefore, we speculated that APOE may participate in regulating autophagy in PTC cells, specifically mitophagy. The relevant findings are presented in Figures 4-6. Analysis of TCGA data revealed significant co-expression of APOE with multiple genes related to mitochondrial autophagy (P<0.05, Figure 4A,4B), pointing to a possible link between APOE and mitochondrial autophagy. Evidence from both tissue and cellular analyses supported an association between APOE expression and mitophagy-related changes. IHC results indicated increased Beclin1 expression in PTC tissues, with concurrent reductions in the mitochondrial outer membrane protein TOMM20 and autophagy receptor p62 immunoreactivity (P<0.05; Figure 4C,4D). Western blot analysis revealed an increase in the LC3-II/LC3-I ratio and Beclin1 levels upon APOE expression, while a decrease in p62, TIM23, and TOMM20 expression was observed (P<0.05, Figure 4E,4G). Conversely, APOE silencing showed the opposite results (P<0.05; Figure 4F,4H). IF analysis further demonstrated diminished fluorescence intensity of Beclin1 in the shAPOE group (Figure 5A), along with enhanced fluorescence intensity of P62, TIM23, and TOMM20 (Figure 5B,5E,5F). Conversely, the APOE OE group exhibited opposite results (Figure 5C,5D,5G,5H). Similar observations were made in xenograft tumor tissues from the shAPOE group, which were obtained from a previously established model and used exclusively for immunohistochemical analysis. Reduced Beclin1 expression and increased accumulation of TOMM20, p62, and TIM23 were also observed (Figure 6E). Functionally, APOE OE was associated with a reduced JC-1 red/green fluorescence ratio (P<0.05, Figure 6A,6J) and decreased total and mitochondrial ROS signals under the tested conditions (P<0.05, Figure 6B,6F,6K,6N). Quantitative TEM analysis demonstrated that the mitophagy ratio per cell was markedly increased in APOE-overexpressing cells relative to control cells (Figure 6H,6P). Furthermore, the opposite trend was identified in the APOE-silenced group (P<0.05; Figure 6C,6D,6G,6I,6L,6M,6O,6Q). Promotion of mitophagy by APOE in PTC cellular models. (A) Correlation network between APOE and mitophagy-associated genes derived from TCGA data. (B) Heatmap depiction of correlations between APOE expression levels and mitophagy-related genes derived from TCGA data. (C) IHC evaluation of mitophagy-related protein abundance in PTC tissues. (D) Quantitative analysis of mitophagy-related protein expression in PTC tissues by IHC. (E) Detection of mitophagy-related proteins in APOE-overexpressing cells by Western blot. (F) Detection of mitophagy-related proteins in APOE-silenced cells by Western blot. (G) Quantitative analysis of mitophagy-related protein expression in APOE-overexpressing cells by Western blot. (H) Quantitative analysis of mitophagy-related protein expression in APOE-silenced cells by Western blot. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. APOE, apolipoprotein E; IHC, immunohistochemistry; IOD, integrated optical density; KEGG, Kyoto Encyclopedia of Genes and Genomes; OE, overexpression; OENC, overexpression negative control; PTC, papillary thyroid carcinoma; TCGA, The Cancer Genome Atlas; TPM, transcripts per million. APOE affects the levels of mitophagy marker proteins within PTC cells. (A) Beclin1 expression was detected by IF following APOE knockdown. (B) P62 expression was observed by IF under APOE silencing. (C) Beclin1 levels were examined by IF in cells overexpressing APOE. (D) P62 expression was assessed by IF in APOE-overexpressing cells. (E) TIM23 expression was detected by IF after APOE knockdown. (F) TOMM20 expression was monitored by IF in APOE-silenced cells. (G) TIM23 expression was evaluated by IF upon APOE overexpression. (H) TOMM20 expression was revealed by IF in APOE-overexpressing cells. (I) Quantitative analysis of immunofluorescence intensity in panels (A-H). *, P<0.05; **, P<0.01; ***, P<0.001. APOE, apolipoprotein E; DAPI, 4',6-diamidino-2-phenylindole; IF, immunofluorescence; OE, overexpression; OENC, overexpression negative control; PTC, papillary thyroid carcinoma. APOE regulates mitochondrial function and autophagosome formation in PTC cells. (A) JC-1 fluorescence assay was employed to monitor mitochondrial membrane potential changes in APOE-overexpressing PTC cells. (B) DCFH-DA fluorescence probe analysis of intracellular ROS level changes in APOE-overexpressing cells. (C) Alteration of mitochondrial membrane potential in APOE-silenced PTC cells, as indicated by JC-1 staining. (D) DCFH-DA fluorescence probe analysis of intracellular ROS level changes in APOE-silenced cells. (E) IHC revealed mitophagy-associated protein levels in mouse xenograft sections. (F) Mitochondrial ROS levels in APOE-overexpressing cells, as revealed by MitoSOX Red staining. (G) Mitochondrial ROS levels in APOE-silenced cells, as revealed by MitoSOX Red staining. (H) Transmission electron microscopy analysis revealed ultrastructural changes in mitochondria within APOE-overexpressing cells. Red arrows denote autophagosomes. (I) Transmission electron microscopy analysis demonstrated ultrastructural alterations in mitochondria within APOE-silenced cells. Yellow arrow signifies compromised mitochondrial structural integrity, with red arrow marking autophagosomes. (J) Mitochondrial membrane potential in APOE-overexpressing PTC cells, quantified by JC-1 fluorescence intensity. (K) Intracellular ROS levels in APOE-overexpressing cells, quantified by DCFH-DA fluorescence intensity. (L) Mitochondrial membrane potential in APOE-silenced PTC cells, quantified by JC-1 fluorescence intensity. (M) Intracellular ROS levels in APOE-silenced cells, quantified by DCFH-DA fluorescence intensity. (N) Mitochondrial ROS levels in APOE-overexpressing cells, quantified by MitoSOX Red fluorescence intensity. (O) Quantitative analysis of mitochondrial ROS in APOE-silenced cells, as assessed by MitoSOX Red fluorescence intensity. (P) Quantitative analysis of mitophagy in APOE-overexpressing cells, based on the number of mitophagosomes per cell. (Q) Quantitative analysis of mitophagy in APOE-silenced cells, based on the number of mitophagosomes per cell. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. APOE, apolipoprotein E; DAPI, 4',6-diamidino-2-phenylindole; DCFH-DA, 2',7'-dichlorodihydrofluorescein diacetate; IHC, immunohistochemistry; OE, overexpression; OENC, overexpression negative control; PTC, papillary thyroid carcinoma; ROS, reactive oxygen species. APOE promotes mitophagy of PTC cells through activation of the PINK1/Parkin signaling pathway Although our preceding results supported an association between APOE and mitophagy-related changes, the underlying regulatory mechanism remained unclear. To gain insight into APOE-mediated mitophagy, we assessed the levels of pivotal proteins within the PINK1/Parkin signaling pathway in both OE-APOE and KD-APOE groups, and the relevant results are shown in Figure 7. Western blot analysis indicated that APOE OE increased the p-AMPK/AMPK ratio, decreased the p-mTOR/mTOR ratio, and was accompanied by upregulation of PINK1 and Parkin protein expression (P<0.05; Figure 7A,7C). Similarly, significant elevation of PINK1 and Parkin expression was observed in the OE-APOE group, as revealed by RT-qPCR (P<0.05; Figure 7G). Conversely, the shAPOE group exhibited the opposite trend (P<0.05; Figure 7B,7D,7H). To assess whether APOE regulates mitophagy via the PINK1/Parkin pathway, we performed intervention experiments in APOE-overexpressing cells that exhibited enhanced mitophagy. Two subgroups were defined: a DMSO-treated control group and an MG149-treated group used to interfere with mitophagy-related signaling. Analysis revealed that MG149 treatment markedly attenuated the mitophagy-related changes induced by APOE OE, the enhanced mitophagy induced by APOE OE was significantly counteracted compared to that in contrast to the DMSO group. Immunoblotting confirmed this inhibitory effect, showing that in the MG149-treated group, Beclin1 expression and the LC3-II/LC3-I ratio were markedly decreased, while P62, TIM23, and TOMM20 were significantly upregulated relative to those in the DMSO group (P<0.05, Figure 7E,7F). Consistently, TEM revealed markedly fewer autophagic structures in the MG149-treated group than in the DMSO group (Figure 7K). MG149-induced recovery of mitochondrial membrane potential was reflected in an elevated red/green fluorescence ratio, indicating improved mitochondrial function relative to DMSO-treated cells (P<0.05, Figure 7I,7L). Moreover, intracellular ROS levels were significantly elevated in the MG149-treated group compared to those in the DMSO group (P<0.05, Figure 7J,7M). These results indicated that MG149 treatment reversed the mitophagy-related changes observed in APOE-overexpressing cells. Our findings suggest that APOE promotes mitophagy-related changes in PTC cells, possibly through modulation of the AMPK/mTOR axis and concomitant upregulation of PINK1/Parkin axis. APOE is associated with mitophagy-related changes and PINK1/Parkin signaling in PTC cells. (A) Protein expression related to the AMPK/mTOR and PINK1/Parkin signaling axis was assessed in APOE-overexpressing TPC-1 cells by Western blot. (B) Western blot analysis in APOE-silenced K1 cells revealed changes in the AMPK/mTOR and PINK1/Parkin signaling axes. (C) Quantitative analysis of AMPK/mTOR and PINK1/Parkin signaling-related protein levels in APOE-overexpressing TPC-1 cells, assessed by Western blot. (D) Quantification of AMPK/mTOR and PINK1/Parkin signaling protein levels in APOE-silenced K1 cells, as determined by Western blot. (E) Western blot revealed mitophagy-associated proteins in APOE-overexpressing cells treated with MG149. (F) Quantitative analysis of mitophagy-associated protein expression in APOE-overexpressing cells following MG149 treatment. (G) RT-qPCR analysis detected PINK1 and Parkin transcripts in APOE-overexpressing cells. (H) RT-qPCR quantification of PINK1 and Parkin mRNA expression in APOE-silenced cells. (I) The mitochondrial membrane potential in APOE-overexpressing cells treated with MG149 was quantified using JC-1 fluorescence intensity. (J) Quantitative analysis of intracellular ROS levels in APOE-overexpressing cells following MG149 treatment, quantified by DCFH-DA fluorescence intensity. (K) TEM was employed to evaluate mitochondrial ultrastructure in APOE-overexpressing cells following MG149 treatment (magnification: ×10,000). (L) JC-1 fluorescent probe assessed changes in mitochondrial membrane potential in APOE-overexpressing cells following MG149 intervention. (M) DCFH-DA fluorescent probe detected ROS levels in APOE-overexpressing cells after MG149 intervention. ns, P≥0.05; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. APOE, apolipoprotein E; DAPI, 4',6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; IHC, immunohistochemistry; ns, not significant; OE, overexpression; OENC, overexpression negative control; PTC, papillary thyroid carcinoma; ROS, reactive oxygen species; RT-qPCR, quantitative real-time polymerase chain reaction; TEM, transmission electron microscopy. APOE enhances PTC cell growth and suppresses apoptosis through increased mitophagy Previous studies have shown that APOE enhances the growth of PTC while inhibiting apoptotic processes. To investigate whether this effect depends on mitophagy, we treated APOE-overexpressing cells with the mitophagy inhibitor 3MA, and the relevant results are shown in Figure 8. The resulting changes in cell proliferation and apoptosis were evaluated. The cells were categorized into two subgroups: a control group treated with DMSO, and an 3MA-treated group to suppress mitophagy. The results from the colony formation assays and CCK-8 consistently demonstrated that 3MA, an inhibitor of mitophagy, markedly diminished the enhanced cellular growth induced by APOE upregulation, in comparison to the DMSO group (P<0.05, Figure 8A,8B,8F). To confirm whether APOE suppressed apoptosis in PTC cells via mitophagy, western blot analysis and Annexin V-FITC/PI staining assays were performed. 3MA-induced modulation of apoptosis was evidenced by Western blot, with upregulation of Bax, Caspase-3, and Cleaved-Caspase-3 accompanied by downregulation of Bcl-2, indicating activation of the apoptotic pathway (P<0.05, Figure 8D,8E). Consistently, flow cytometry quantification of Annexin V–FITC/PI staining revealed a significantly elevated apoptosis rate in the 3MA-treated group relative to DMSO-treated cells, reflecting enhanced apoptotic cell death. These findings indicated that inhibition of mitophagy markedly promotes apoptosis in PTC cells (P<0.05, Figure 8C,8G). The activation of mitophagy by APOE leads to enhanced PTC cell growth and inhibition of programmed cell death, collectively supporting its role in promoting cell survival. APOE-mediated mitophagy facilitates PTC cell growth and suppresses apoptotic cell death. (A) CCK-8 analysis evaluating the impact of 3MA intervention regarding the proliferative capacity within APOE-overexpressing cells. (B) Colony formation experiment detecting the colony-forming ability in APOE-overexpressing cell lines after 3MA intervention. (C) Flow Cytometry assessed the impact of 3MA on apoptosis in the APOE overexpression group. (D) Western blot analysis of apoptosis-associated proteins in APOE-overexpressing cells following 3MA treatment. (E) Quantification of apoptosis-related protein expression in APOE-overexpressing cells post-3MA treatment. (F) Assessment of colony-forming ability in APOE-overexpressing cells after 3MA treatment. (G) Flow cytometry-based quantification of apoptosis in APOE-overexpressing cells following 3MA treatment. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001. APOE, apolipoprotein E; CCK-8, Cell Counting Kit-8; DMSO, dimethyl sulfoxide; OE, overexpression; OENC, overexpression negative control; OD, optical density; PTC, papillary thyroid carcinoma; ROS, reactive oxygen species. Discussion As a pleiotropic protein, APOE plays an important role in lipid metabolism, neurodegenerative diseases, and immune regulation (19-21). Among these, the ε4 allele of APOE is regarded as the predominant hereditary factor predisposing individuals to sporadic Alzheimer’s disease, exerting a stronger effect than other known loci (22). Recently, the contribution of APOE to tumor development and growth has attracted growing attention. Previous studies have indicated that APOE contributes to oncogenesis by promoting cell proliferation and dissemination in non-small cell lung and colorectal cancers (23,24). In the present study, elevated APOE expression was observed in PTC tissues, with levels significantly surpassing those in adjacent normal tissues and normal thyroid cell lines. This finding suggests a potential role of APOE in PTC tumorigenesis and highlights its potential as a molecular marker for distinguishing PTC from normal tissues. Furthermore, this finding was validated not only in clinical specimens but also in TCGA database. Notably, APOE demonstrated favorable diagnostic performance in THCA, with an area under the curve (AUC) of 0.779, suggesting its potential value as a diagnostic biomarker. To investigate the functional mechanisms of APOE in THCA, we performed gene enrichment and immune cell infiltration analyses. Gene enrichment analysis suggested that APOE may participate in metabolic reprogramming and disease progression in THCA by influencing cell membrane transport functions, particularly the transport of metabolites or signaling molecules. Immune infiltration profiling has revealed a robust association between APOE expression and macrophage enrichment, highlighting its functional significance in the cancer microenvironment. Taken together, the data reveal the multifaceted functions of APOE in THCA progression, with potential involvement in both metabolic regulation and immune-related pathways, indicating a broader role in tumor biology. Notably, immune infiltration analysis revealed a robust association between APOE expression and macrophage enrichment, suggesting a potential link between APOE-related tumor metabolic regulation and the macrophage compartment within the tumor microenvironment. Given that TAMs are key regulators of tumor progression and immune evasion (25), it is plausible that APOE-driven mitophagy may contribute to shaping TAM-associated phenotypes through metabolic reprogramming and cytokine-mediated crosstalk (26,27). Conversely, TAM-derived inflammatory signals and metabolic cues may also modulate mitochondrial quality control and mitophagy in tumor cells, thereby establishing a potential bidirectional regulatory loop between tumor cells and macrophages. Although the present study primarily focused on the tumor cell-intrinsic role of APOE in regulating mitophagy, these observations highlight a previously underexplored link between APOE-induced mitophagy and TAM biology, warranting further mechanistic investigation of PTC. Chen et al. reported that APOE4 contributes to Alzheimer’s disease by disrupting mitochondrial function and dynamics (28). Mitophagy plays a fundamental role in eliminating damaged mitochondria and facilitating mitochondrial renewal, both critical for cellular homeostasis (29). In this process, P62, acts as a selective autophagy receptor (30,31), binding ubiquitinated cargo and targets it to the autophagosome for lysosomal degradation, thereby undergoing self-degradation (32). P62 associates with LC3 via LIR to deliver ubiquitin-tagged substrates into autophagic vesicles for clearance (33). In addition, as core components of mitochondrial membrane protein complexes, alterations in TOMM20 and TIM23 expression levels are frequently utilized as key indicators for evaluating mitophagy activity. Specifically, TOMM20, a subunit of the outer membrane TOM complex, mediates precursor protein import into mitochondria, whereas TIM23 serves as an essential part of the mitochondrial inner membrane translocase, aiding in protein transport into the mitochondrial matrix (34). Beclin1 also plays a pivotal role in initiating autophagy, functioning as an essential subunit within the class III PI3K complex (35). In this study, we explored the potential relationship between APOE and mitophagy in PTC. Immunohistochemical analysis revealed the altered expression of p62, TOMM20, and Beclin1 in PTC tissues, suggesting that APOE may influence mitophagy regulation. Furthermore, TCGA database analysis revealed significant co-expression of APOE and multiple mitophagy-related genes. Consistent with these findings, experiments using APOE-overexpressing and APOE-knockdown PTC cell models revealed corresponding changes in mitophagy-related biomarkers. Collectively, these results support an association between APOE expression and mitophagy-related changes in PTC cells. In the present study, APOE OE was associated with altered mitochondrial membrane potential and reduced overall mitochondrial ROS levels in PTC cells. Since mitochondrial depolarization may serve as an initiating signal for mitophagy, whereas subsequent clearance of damaged mitochondria may influence the overall mitochondrial status detected a later time points, these findings should be interpreted as net mitophagy-associated changes rather than a static end-state of all remaining mitochondria. The AMPK/mTOR pathway is a key regulation of intracellular and mitochondrial autophagy. AMPK activation promotes autophagy, whereas mTOR inhibits it (36). The canonical mitophagy mechanism is mediated through the PINK1/Parkin pathway. Upon mitochondrial damage, PINK1 accumulates on the outer membrane, where it recruits Parkin and initiates a ubiquitination cascade, leading to the activation of mitochondrial autophagy (37). Chen et al. reported that SMYD2 drives mitophagy activates PINK1/Parkin signaling cascade, thereby preserving the stem-like properties of bladder cancer stem cells (38). Based on this, we examined whether APOE-associated mitophagy-related changes in PTC might involve the AMPK/mTOR and PINK1/Parkin signaling axes. APOE OE increases AMPK phosphorylation, decreases mTOR phosphorylation and upregulates PINK1 and Parkin. Pharmacological intervention with MG149 attenuated these changes, as confirmed by western blotting, TEM, and IF. These findings suggest that APOE may promote mitophagy-related changes in PTC partly through modulation of the AMPK/mTOR axis and PINK1/Parkin-associated signaling. However, the precise molecular link still requires further pathway-specific validation. Mitophagy plays a multifaceted role in oncogenesis, with the potential to promote or inhibit malignant development. From one perspective, it eliminates damaged mitochondria, maintains ROS homeostasis and energy supply, thereby supporting tumor cell survival under stress conditions (39). Conversely, excessive autophagic process can culminate in programmed cell death (40). Previous studies suggest APOE facilitates PTC progression by stimulating cell growth and inhibiting apoptotic pathways (10). In light of these observations, we sought to determine if APOE’s enhancement of malignant traits in PTC cells is reliant on mitophagy. To this end, we exposed OE-APOE cells to the mitophagy-suppressing compound, 3MA. The proliferation and apoptosis were evaluated using colony formation assays, the CCK-8 assay, western blotting, and flow cytometry. The results demonstrated that inhibiting mitophagy significantly reversed the enhanced proliferation and suppressed apoptosis induced by APOE OE. Collectively, these findings indicated that APOE promotes the malignant progression of PTC by regulating mitophagy. From a mechanistic perspective, the identification of an APOE-associated mitophagy axis provides additional insight into PTC biology. Given that APOE was associated with malignant progression and mitophagy-related changes in our model, this pathway may warrant further preclinical investigation. From the translational and clinical perspectives, these mechanistic findings have several potential therapeutic implications. The PINK1/Parkin signaling pathway is a central regulator of mitochondrial quality control and has increasingly been recognized as a potentially druggable pathway in multiple diseases (41). Given that our data support a pro-tumor role of PINK1/Parkin-mediated mitophagy in PTC, therapeutic inhibition of this mitophagy program may represent a promising strategy to suppress tumor progression by disrupting mitochondrial quality control and metabolic adaptation in tumor cells (42). Moreover, accumulating evidence indicates that dysregulated mitophagy contributes to therapy resistance and immune evasion in cancer (43), raising the possibility that targeting the APOE-PINK1/Parkin-associated mitophagy axis identified in this study may have potential value in combination strategies with conventional therapies or immunotherapy; however, this possibility requires further validation in dedicated therapeutic models. In addition, APOE expression could potentially serve as a biomarker for patient stratification, enabling the identification of patients who may benefit from therapeutic interventions targeting mitochondrial quality control pathways (44). Nevertheless, further in vivo studies and clinical validation are required to fully establish the translational applicability and safety of targeting mitophagy-related pathways in PTC. Despite the progress made in this study, several limitations should be acknowledged. First, although we validated the cancer-promoting effect of APOE and explored its underlying mechanisms in PTC using multiple approaches, the present conclusions were mainly derived from cell-based experiments together with small-scale clinical samples. Second, although our data support an association between APOE expression and PINK1/Parkin-related mitophagy, more specific functional assays are still required to validate this pathway with greater mechanistic precision. Third, the mitochondrial membrane potential and ROS data in this study were obtained as overall cellular readouts under the tested conditions, and dynamic analyses will be needed in future work to further clarify the temporal relationship between mitochondrial depolarization, mitophagy, and redox changes. Finally, no targeted therapeutic intervention or drug-efficacy studies were performed in the current work; therefore, the APOE-associated pathway may represent a promising direction for future translational research in PTC. Further investigations in larger clinical cohorts, together with prognostic analyses, are warranted to confirm the present findings and to evaluate the potential of APOE as a biomarker in PTC. Conclusions Our findings revealed that APOE is associated with enhanced PINK1/Parkin-related mitophagy, increased proliferation, and reduced apoptosis in PTC cells. These results provide mechanistic insight into APOE-mediated tumor progression and support further preclinical investigation of APOE-related mitochondrial quality-control pathways in PTC. Supplementary The article’s supplementary files as Available at https://tcr.amegroups.com/article/view/10.21037/tcr-2026-0796/prf